Search is Powered by Google
Cancer / Oncology News

Proton Therapy Lowers Chance Of Later Cancers

Main Category: Cancer / Oncology
Also Included In: Radiology / Nuclear Medicine
Article Date: 23 Sep 2008 - 4:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:4 and a half stars

4.5 (2 votes)

Article Opinions: 0 posts

Patients who are treated with proton therapy (a specialized type of external beam radiation therapy using protons rather than X-rays to treat cancer) decreases the risk of patients developing a secondary cancer by two-fold, compared to being treated with standard photon radiation treatment, according to a first-of-its-kind study presented September 22, 2008, at the American Society for Therapeutic Radiology and Oncology's 50th Annual Meeting in Boston.

This study contradicts recent theories that have suggested that proton radiation might actually increase - instead of decrease - the incidence of secondary cancers because of what is called scatter radiation. When proton radiation is delivered, neutrons are produced by nuclear interactions and are therefore scattered as a result.

"This study could have a substantial impact on the care of patients," Nancy Tarbell, M.D., senior author of the study and a radiation oncologist at the Massachusetts General Hospital in Boston, said. "Since cancer patients are surviving for longer periods of time, side effects of therapy are becoming increasingly important for doctors to consider when developing treatment plans. Since this is a retrospective study, however, we will need additional studies to further prove this hypothesis."

Photon radiation is the standard external beam radiation therapy treatment, while proton radiation is a more targeted form of external beam radiation which delivers less radiation to bordering normal structures. During external beam radiation therapy, a beam of radiation is directed through the skin to the cancer and the immediate surrounding area in order to destroy the main tumor and any nearby cancer cells.

The retrospective cohort study matched 503 patients who underwent Harvard Cyclotron proton radiation treatment with 1,591 patients treated with photon radiation therapy from the Surveillance, Epidemiology, and End Results (SEER) cancer registry from 1974 to 2001. According to the study, 6.4 percent of patients who underwent proton therapy developed a secondary cancer while 12.8 percent of patients who had photon treatment developed another type of cancer.

For more information on radiation therapy for cancer, visit http://www.rtanswers.org.

The abstract, "Comparative Analysis of Second Malignancy Risk in Patients Treated with Proton Therapy versus Conventional Photon Therapy," was presented in a scientific session at 10:15 a.m. on Monday, September 22, 2008.




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...